Cha Hyejung, Park Hee Chul, Yu Jeong Il, Kim Tae Hyun, Nam Taek-Keun, Yoon Sang Min, Yoon Won Sup, Kim Jun Won, Kim Mi Sook, Jang Hong Seok, Choi Youngmin, Kim Jin Hee, Kay Chul Seung, Jung Inkyung, Seong Jinsil
Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Cancer Res Treat. 2017 Jan;49(1):61-69. doi: 10.4143/crt.2016.097. Epub 2016 Jun 13.
The aim of this study was to examine patterns of radiotherapy (RT) in Korean patients with hepatocellular carcinoma (HCC) according to the evolving guideline for HCC established by the Korean Liver Cancer Study Group-National Cancer Center (KLCSG-NCC).
We reviewed 765 patients with HCC who were treated with RT between January 2011 and December 2012 in 12 institutions.
The median follow-up period was 13.3 months (range, 0.2 to 51.7 months). Compared with previous data between 2004 and 2005, the use of RT as a first treatment has increased (9.0% vs. 40.8%). Increased application of intensity-modulated RT resulted in an increase in radiation dose (fractional dose, 1.8 Gy vs. 2.5 Gy; biologically effective dose, 53.1 Gy vs. 56.3 Gy). Median overall survival was 16.2 months, which is longer than that reported in previous data (12 months). In subgroup analysis, treatments were significantly different according to stage (p < 0.001). Stereotactic body RT was used in patients with early HCC, and most patients with advanced stage were treated with three-dimensional conformal RT.
Based on the evolving KLCSG-NCC practice guideline for HCC, clinical practice patterns of RT have changed. Although RT is still used mainly in advanced HCC, the number of patients with good performance status who were treated with RT as a first treatment has increased. This change in practice patterns could result in improvement in overall survival.
本研究旨在根据韩国肝癌研究组-国立癌症中心(KLCSG-NCC)制定的不断演变的肝细胞癌(HCC)指南,研究韩国HCC患者的放射治疗(RT)模式。
我们回顾了2011年1月至2012年12月期间在12家机构接受RT治疗的765例HCC患者。
中位随访期为13.3个月(范围0.2至51.7个月)。与2004年至2005年的先前数据相比,RT作为首次治疗的使用有所增加(9.0%对40.8%)。调强放疗应用的增加导致放射剂量增加(分次剂量,1.8 Gy对2.5 Gy;生物等效剂量,53.1 Gy对56.3 Gy)。中位总生存期为16.2个月,长于先前数据报道的12个月。在亚组分析中,治疗根据分期有显著差异(p<0.001)。早期HCC患者采用立体定向体部放疗,大多数晚期患者采用三维适形放疗。
基于不断演变的KLCSG-NCC HCC实践指南,RT的临床实践模式发生了变化。尽管RT仍主要用于晚期HCC,但作为首次治疗接受RT的身体状况良好的患者数量有所增加。这种实践模式的变化可能会导致总生存期的改善。